Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Jan 19:gutjnl-2025-337846.
doi: 10.1136/gutjnl-2025-337846. Online ahead of print.

Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn's and Colitis (PREdiCCt) prospective cohort study

Collaborators, Affiliations
Free article

Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn's and Colitis (PREdiCCt) prospective cohort study

Nathan Constantine-Cooke et al. Gut. .
Free article

Abstract

Background: IBD is characterised by recurrent flares, but evidence on whether modifiable dietary factors influence flare risk is limited.

Objective: The PREdiCCt study was designed to examine demographic, clinical and dietary factors associated with disease flare among patients with IBD in self-reported remission.

Design: Multicentre, prospective cohort study conducted across 47 UK centres. Patients with Crohn's disease (CD), ulcerative colitis (UC) or IBD unclassified (IBDU) in self-reported remission were prospectively followed up. The baseline diet was assessed using a validated food frequency questionnaire. The primary outcome was time to patient-reported flare (captured by monthly IBD-Control) and objective flare (clinical flare plus C-reactive protein >5 mg/L and/or faecal calprotectin (FC) >250 µg/g with treatment escalation). Associations were evaluated using Cox frailty models adjusted for demographic, clinical and biochemical variables, including baseline FC.

Results: Between November 2016 and March 2020, 2629 participants (1370 CD; 1259 UC/IBDU) were enrolled and followed up for a median of 4.1 years (IQR 3.0-5.0). Baseline FC was strongly associated with patient-reported flares (FC ≥250 µg/g: adjusted HR (aHR) 2.22; FC 50-250 µg/g: aHR 1.52 (reference <50 µg/g)) and objective flares (FC ≥250 µg/g: aHR 3.25; FC 50-250 µg/g: aHR 1.98). In UC, higher total meat intake was associated with increased risk of objective flares (highest versus lowest quartile: aHR 1.95, 95% CI 1.07 to 3.56). No consistent associations were observed for ultraprocessed foods, fibre or polyunsaturated fatty acids and flare.

Conclusion: Higher habitual meat intake was associated with increased risk of objective flare in UC, suggesting diet may contribute to flare susceptibility in specific patient groups.

Trial registration number: NCT03282903.

Keywords: CROHN'S DISEASE; DIET; INFLAMMATORY BOWEL DISEASE; ULCERATIVE COLITIS.

PubMed Disclaimer

Conflict of interest statement

Competing interests: BG has served as a consultant to AbbVie, Pfizer, Roche and Galapagos and has served as a speaker for AbbVie, Janssen, Takeda, Pfizer, Gilead, Roche and Galapagos. NP has served as a speaker for AbbVie, Janssen, Pfizer, Takeda, Ferring and Fresenius Kabi and received travel support from AbbVie, Janssen and Takeda. G-RJ has received speaking fees for Janssen, Ferring, Fresenius, Takeda and AbbVie. NAK has served as an advisory board member and/or speaker for AbbVie, Bristol Myers Squibb, Celltrion, Falk, Galapagos, Johnson & Johnson, Pfizer, Pharmacosmos, Takeda and Tillotts. CM has received speaking and advisory board fees for AbbVie, Galapagos, Janssen and Tillotts. SIS has served as an advisory board member and/or speaker for AbbVie, Demo SA, Johnson & Johnson, Lilly, Pfizer and Takeda. DG has received speaker honouraria and advisory board fees from Pfizer, AbbVie, Janssen, Takeda and Dr Falk. AJ holds voluntary committee roles within the Nutrition Society, British Nutrition Foundation and Association for the Study of Obesity. CW has undertaken consultancy work for AB Science for which his department has received a fee and holds committee roles within the Medicines and Healthcare products Regulatory Agency (MHRA). CWL has acted as a consultant to AbbVie, Janssen, Takeda, Pfizer, Galapagos, Eli Lilly, Bristol Myers Squibb, Boehringer Ingelheim, Sandoz, Novartis, GSK, Gilead, Vifor Pharma and Dr. Falk; he has received speaking fees and travel support from Pfizer, Janssen, AbbVie, Eli Lilly, Galapagos, MSD, Takeda, Shire, Ferring and Dr. Falk. All other authors have no conflicts of interest to disclose.

Associated data

LinkOut - more resources